These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 12480612)
1. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B; Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612 [TBL] [Abstract][Full Text] [Related]
2. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
3. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Gibson RL; Emerson J; Mayer-Hamblett N; Burns JL; McNamara S; Accurso FJ; Konstan MW; Chatfield BA; Retsch-Bogart G; Waltz DA; Acton J; Zeitlin P; Hiatt P; Moss R; Williams J; Ramsey BW Pediatr Pulmonol; 2007 Jul; 42(7):610-23. PubMed ID: 17534969 [TBL] [Abstract][Full Text] [Related]
4. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
5. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
6. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Gappa M; Steinkamp G; Tümmler B; von der Hardt H Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515 [TBL] [Abstract][Full Text] [Related]
7. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222 [TBL] [Abstract][Full Text] [Related]
8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. Al-Aloul M; Nazareth D; Walshaw M J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814 [TBL] [Abstract][Full Text] [Related]
9. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404 [TBL] [Abstract][Full Text] [Related]
10. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274 [TBL] [Abstract][Full Text] [Related]
11. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Bilton D; Henig N; Morrissey B; Gotfried M Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030 [TBL] [Abstract][Full Text] [Related]
12. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
13. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869 [TBL] [Abstract][Full Text] [Related]
14. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Parkins MD; Elborn JS Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683 [TBL] [Abstract][Full Text] [Related]
16. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Ratjen F; Munck A; Kho P; Angyalosi G; Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Ballmann M; Smyth A; Geller DE Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546 [TBL] [Abstract][Full Text] [Related]
18. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Adeboyeku D; Jones AL; Hodson ME J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166 [TBL] [Abstract][Full Text] [Related]
20. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cheer SM; Waugh J; Noble S Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]